drugset / Trial / NCT05348915
A Study to Evaluate the Long-term Safety of Inclacumab Administered to Participants With Sickle Cell Disease
NaSingle-groupOpen-labelTreatment
Summary
This study is an open-label study to evaluate the safety of long-term administration of inclacumab in participants with sickle cell disease (SCD). Participants in this study will have completed a prior study of inclacumab.
Timeline
- Start
- 2022-03-29
- Primary completion
- 2025-11-07
- Completion
- 2025-11-07
Outcome
Outcome not reported
Stopped (Business): “Sponsor decision to terminate study based on results of parent study GBT2104-131.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Inclacumab | Monoclonal antibody | 30 mg/kg | Intravenous |